lincomycin has been researched along with imipenem, anhydrous in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Guo, Y; Jia, G; Li, L; Wang, J; Wei, L; Xu, X; Yang, Y; Yu, Q; Zhou, Y | 1 |
| Kuroe, K; Nakaji, S; Ogasawara, H; Saito, S; Sakata, Y; Sawada, Y; Shinagawa, H; Soma, N; Takami, H; Tsushima, K | 1 |
| Maskell, JP; Nasu, M; Williams, JD; Williams, RJ | 1 |
| Avila-Campos, MJ; Carvalho, MA; Zelante, F | 1 |
| Al-Ebous, AD; Al-Jahmi, M; Al-Zuriqat, AN; Hiasat, B; Sarayrah, M | 1 |
2 trial(s) available for lincomycin and imipenem, anhydrous
| Article | Year |
|---|---|
[A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases].
Topics: Adolescent; Adult; Aged; Aztreonam; Cilastatin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Imipenem; Lincomycin; Male; Middle Aged; Neoplasms; Opportunistic Infections; Pneumonia; Sepsis; Urinary Tract Infections | 1992 |
Management of diabetic foot in a Jordanian hospital.
Topics: Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Ceftazidime; Chemotherapy, Adjuvant; Debridement; Diabetic Foot; Drug Combinations; Drug Monitoring; Humans; Imipenem; Kidney Diseases; Length of Stay; Lincomycin; Metronidazole; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Severity of Illness Index; Treatment Outcome; Wound Healing; Wound Infection | 2005 |
5 other study(ies) available for lincomycin and imipenem, anhydrous
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Escherichia coli; Flavonols; Meropenem; Microbial Sensitivity Tests | 2022 |
In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp.
Topics: Anti-Bacterial Agents; Bacteroides; Bacteroides fragilis; beta-Lactams; Cefotaxime; Cefoxitin; Cefsulodin; Cephalosporins; Cephamycins; Imipenem; Lincomycin; Metronidazole; Moxalactam | 1981 |
Distribution of biotypes and antimicrobial susceptibility of Actinobacillus actinomycetemcomitans.
Topics: Adolescent; Adult; Aggregatibacter actinomycetemcomitans; Anti-Bacterial Agents; Antitrichomonal Agents; Bacterial Typing Techniques; Cefoxitin; Cephamycins; Clindamycin; Dental Plaque; Drug Resistance, Microbial; Erythromycin; Female; Humans; Imipenem; Lincomycin; Male; Metronidazole; Microbial Sensitivity Tests; Penicillin G; Penicillins; Periodontitis; Tetracycline; Thienamycins | 1995 |